09.05.2017

AiCuris Initiates U.S. Clinical Phase 2 Trial with Oral Pritelivir
Opening of the first site in its clinical phase 2 study, PRIOH-1

more ...

08.03.2017

AiCuris selects Mercachem as preferred medicinal chemistry partner

more ...

17.01.2017

AiCuris Announces Publication of Phase 2 Clinical Trial Results of Investigational Anti-Herpes Simplex Virus Agent Pritelivir in JAMA
Study results clearly supported pritelivir to be more effective than alacyclovir for suppression of herpes simplex virus (HSV) genital shedding in patients with frequent recurrences

more ...

04.01.2017

AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria
Program supported by the Innovative Medicines Initiative

more ...